Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with or without bevacizumab versus sunitinib in untreated advanced renal cell carcinoma
2013-003167-58Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) comparing Atezolizumab + bevacizumab, Atezolizumab monotherapy and Sunitinib (3 arms). Primary endpoint: Progression-free survival. Started Dec 2013; status: completed.
02
Drugs
atezolizumabbevacizumabsunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2013-003167-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003167-58.